Latest news

• NICE recommends two drugs for ovarian cancer but rejects three

  But the cost-effectiveness body rejected GlaxoSmithKline's Hycamtin (topotecan), PharmaMar's Yondelis (trabectedin) and Lilly's Gemzar (gemcitabine) for treating the first recurrence of platinum-sensitive ovarian cancer.

• Merck KGaA, Threshold gain FDA fast-track review

  Gemzar (gemcitabine).

• NICE rejects pancreatic cancer regimen over cost concerns

  Charity says draft decision to deny Abraxane/Gemzar combo is a ‘backwards step’ for the NHS pricing body. ... survival (OS) rates of just over two months, compared to Gemzar on its own.

• NICE rejection of three ovarian cancer drugs stands

  Agency will still not recommend Gemzar, Hycamtin and Yondelis for the disease. ... NICE has over the past three years rejected three medicines for the disease: Lilly's Gemzar (gemcitabine), GlaxoSmithKline's Hycamtin (topotecan), both of which are also

• NICE knocks back Celgene's Abraxane in pancreatic cancer

  The current standard of care is the FOLFIRINOX chemotherapy regimen or, where its side effects are too severe, Gemzar with our without capecitabine. ... QALY gained for nab-paclitaxel plus Gemzar compared with Gemzar alone at £78, 500 - well over its